Physician profile
Eric Brahin
NPI 1710201264
$27,543.06
in general payments reported to CMS, 2019-2025
67 companies · $4,077 in 2025
The $4,077 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,688 · 2020: $3,582 · 2021: $3,740 · 2022: $4,009 · 2023: $4,239 · 2024: $4,208 · 2025: $4,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,523.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,662.44 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Novartis Pharmaceuticals Corporation | $1,591.64 | 2019-2025 | |
| Emd Serono, INC. | $1,582.81 | 2019-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $1,566.13 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Abbvie INC. | $1,552.29 | 2019-2025 | Qulipta, Botox, Ubrelvy |
| Acadia Pharmaceuticals INC | $1,390.35 | 2019-2025 | Nuplazid, Daybue |
| Celgene Corporation | $1,353.15 | 2021-2025 | Zeposia |
| Biogen, INC. | $1,315.23 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Livanova USA, INC. | $1,228.11 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Amneal Pharmaceuticals LLC | $1,056.42 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Pfizer INC. | $1,029.72 | 2019-2025 | |
| Genentech USA, INC. | $1,010.41 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Amgen INC. | $936.91 | 2019-2023 | Aimovig |
| Sk Life Science, INC. | $688.63 | 2020-2025 | |
| Eisai INC. | $631.59 | 2020-2025 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Brahin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.